Breaking News, Collaborations & Alliances

Amphista Therapeutics Attains First Discovery Milestone in BMS Alliance

Under collaboration leveraging Amphista's next-gen targeted protein degradation platform, BMS is granted a global exclusive license to the resulting degraders.

Amphista Therapeutics, a provider of next generation targeted protein degradation (TPD) approaches, delivered the first discovery milestone under its collaboration and license agreement with Bristol-Myers Squibb (BMS), triggering a payment for achieving the milestone. The collaboration and license agreement announced in May 2022, included a $30 million upfront payment, the potential for up to $1.25 billion in performance-based milestone payments and payment for a limited expansion of the coll...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters